Treatment with fulvestrant and the tamoxifen metabolite 4-OHT upregulated Fas and TRAIL-R1/R2 and resulted in increased NK cell-mediated lysis of breast cancer cells regardless of estrogen receptor (ER) status [176]. Here, ESR1 is linked to breast carcinoma.